Scienture Ships 10 mg REZENOPY Nasal Spray to Wholesalers, Targets $144M Market
SCNX•Scienture completed manufacturing of commercial inventory for its 10 mg REZENOPY nasal spray and will begin U.S. wholesaler shipments in July, targeting an August launch. The highest-dose FDA-approved naloxone spray enters a $144 million market with nearly 9.8 million annual units and coverage for 100 million lives.
1. Commercial Inventory Readiness
On July 9, Scienture completed manufacturing of its launch inventory for REZENOPY (naloxone hydrochloride) Nasal Spray 10 mg and will ship units to U.S. pharmaceutical wholesalers later this month, paving the way for nationwide distribution.
2. Market Opportunity
The U.S. naloxone market generated about $144 million in annual sales across roughly 9.8 million units, presenting a significant commercial opportunity for REZENOPY as the highest-dose FDA-approved naloxone nasal spray.
3. Payer Access Expansion
Scienture has secured potential payer coverage for 100 million lives, enhancing access for pharmacies, healthcare providers, first responders and community organizations ahead of the August commercial launch.
4. Commercial Strategy Alignment
Following the October 2025 launch of Arbli™, REZENOPY’s rollout represents the next phase in Scienture’s specialty pharmaceutical expansion, aimed at driving long-term prescription growth and new revenue streams.
